Articles By Anuja Singh
Is Merck’s £1B Exit Forcing AstraZeneca, Lilly, and Sanofi to Rethink UK’s Life Sciences…
Key Insights Merck Triggers Domino Effect with £1B Withdrawal Merck’s decision to abandon its £1-billion London R&D facility…
By
Can DeepMind’s Demis Hassabis Slash Drug Discovery Timelines From Years to Months—And What Does…
Key Highlights: What Hassabis Says: A Turning Point for Drug DiscoveryDemis Hassabis, CEO of DeepMind, recently told Bloomberg…
Will AbbVie’s Rinvoq Patent Deal Lock Out Generics Until 2037—Securing a $31B Immunology Stronghold?
Key Highlights: Patent Shield Extended Through SettlementsAbbVie has successfully resolved litigation with multiple generic challengers—including Sandoz, Aurobindo, Intas,…
Will Johnson & Johnson’s FDA Approval of INLEXZO™ Redefine Bladder Cancer Care After 40…
Key Highlights: A Breakthrough in Bladder Cancer TreatmentThe U.S. FDA has approved INLEXZO™ (gemcitabine intravesical system), marking the…
Could Johnson & Johnson’s MARIPOSA Trial with RYBREVANT® + LAZCLUZE® Transform First-Line EGFR-Mutated NSCLC…
Key Highlights: Clinical Breakthrough in EGFR-Mutated NSCLCJohnson & Johnson’s Innovative Medicine segment has announced positive results from the…
Can Novo Nordisk’s New Semaglutide and Obesity Pipeline Data at EASD 2025 Redefine ‘Food…
Key Highlights: Scientific Momentum at EASD 2025Novo Nordisk will present 35 abstracts across its diabetes and obesity portfolio…
Is Merck’s £1B Exit Forcing AstraZeneca, Lilly, and Sanofi to Rethink UK’s Life Sciences…
Key Insights Merck Triggers Domino Effect with £1B Withdrawal Merck’s decision to abandon its £1-billion London R&D facility…
Can DeepMind’s Demis Hassabis Slash Drug Discovery Timelines From Years to Months—And What Does…
Key Highlights: What Hassabis Says: A Turning Point for Drug DiscoveryDemis Hassabis, CEO of DeepMind, recently told Bloomberg…
Will AbbVie’s Rinvoq Patent Deal Lock Out Generics Until 2037—Securing a $31B Immunology Stronghold?
Key Highlights: Patent Shield Extended Through SettlementsAbbVie has successfully resolved litigation with multiple generic challengers—including Sandoz, Aurobindo, Intas,…
Will Johnson & Johnson’s FDA Approval of INLEXZO™ Redefine Bladder Cancer Care After 40…
Key Highlights: A Breakthrough in Bladder Cancer TreatmentThe U.S. FDA has approved INLEXZO™ (gemcitabine intravesical system), marking the…
Could Johnson & Johnson’s MARIPOSA Trial with RYBREVANT® + LAZCLUZE® Transform First-Line EGFR-Mutated NSCLC…
Key Highlights: Clinical Breakthrough in EGFR-Mutated NSCLCJohnson & Johnson’s Innovative Medicine segment has announced positive results from the…
Can Novo Nordisk’s New Semaglutide and Obesity Pipeline Data at EASD 2025 Redefine ‘Food…
Key Highlights: Scientific Momentum at EASD 2025Novo Nordisk will present 35 abstracts across its diabetes and obesity portfolio…